Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Aurinia Pharmaceuticals Inc (AUPH) vs Mineralys Therapeutics, Inc. (MLYS)

Aurinia Pharmaceuticals Inc and Mineralys Therapeutics, Inc. are both Biotechnology companies. Aurinia Pharmaceuticals Inc and Mineralys Therapeutics, Inc. are of similar size ($2.4B and $2.2B). Mineralys Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Aurinia Pharmaceuticals Inc trades at 6.9×. Aurinia Pharmaceuticals Inc has the higher net margin (100.8% vs 0.00%) and the higher return on invested capital (40.8% vs 0.00%). Across the 13 metrics below, Aurinia Pharmaceuticals Inc leads on 12 and Mineralys Therapeutics, Inc. on 1.

Valuation

Metric AUPH MLYS Biotechnology median
P/E 6.88 n/m 7.88
P/S 6.87 n/m 11.47
P/B 3.48 3.98 2.52
Price to free cash flow 12.22 n/m 21.16
EV/EBITDA 10.87 n/m 0.74
EV/Sales 5.58 n/m 10.73
Earnings yield 14.54% (16.40%) (28.84%)
Free cash flow yield 8.19% (6.34%) (23.03%)

Profitability

Metric AUPH MLYS Biotechnology median
Gross margin 90.36% — 65.16%
Operating margin 45.15% 0.00% 0.00%
Net margin 100.84% 0.00% 0.00%
Free cash flow margin 56.20% 0.00% 0.00%
Return on equity 66.12% (80.88%) (57.72%)
Return on assets 48.52% (69.67%) (49.22%)
Return on invested capital 40.76% 0.00% 0.00%

Growth

Metric AUPH MLYS Biotechnology median
Revenue growth (TTM) 19.76% — 5.64%
EPS growth (last fiscal year) 5,075.00% 37.43% —
Revenue growth, 5-year CAGR 41.38% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AUPH MLYS Biotechnology median
Debt to equity 0.07 0.18 0.00
Current ratio 5.42 34.46 4.73
Net debt to EBITDA (2.58) 3.85 0.96

Dividend

Metric AUPH MLYS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric AUPH MLYS Biotechnology median
Market cap 2.21b 2.35b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack